HIC1 and cancer: In line with this concept, the potential of HIC1 promoter methylation to act as biomarkers has been assessed in several types of cancers (Chen et al., 2017[6]; Yu et al., 2011[36]; Zheng et al., 2013[39]), albeit with some inconclusiveness in their outcomes.